⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GLUE News
Monte Rosa Therapeutics, Inc. Common Stock
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
globenewswire.com
GLUE
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
GLUE
Form 8-K
sec.gov
GLUE
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
globenewswire.com
GLUE
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
globenewswire.com
GLUE
Form 8-K
sec.gov
GLUE
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
globenewswire.com
GLUE
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
GLUE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
GLUE
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
globenewswire.com
GLUE